Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Rate of Progression in USH2A-related Retinal Degeneration
NCT03146078 · View on ClinicalTrials.gov ↗
Study Summary
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39). RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.
Conditions Studied
Study Locations (14)
Other
- Hospital for Sick Children — Toronto
- Centre hospitalier National d'Ophtalmologie des Quinze-Vingts — Paris
- University of Tubingen — Tübingen
- Radboud University — Nijmegen
- Moorfields Eye Hospital — London
Texas
- Retina Foundation of the Southwest — Dallas
- Baylor Eye Physicians and Surgeons — Houston
California
- University of California, San Francisco — San Francisco
Florida
- Vitreo-Retinal Associates — Gainesville
Maryland
- Wilmer Eye Institute at Johns Hopkins — Baltimore
Massachusetts
- Massachusetts Eye and Ear — Boston
Michigan
- Kellogg Eye Center, University of Michigan — Ann Arbor
Oregon
- OHSU Casey Eye Institute — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2017-08-11 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03146078
The ClinicalTrials.gov registry entry for NCT03146078 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 134 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Usher Syndrome, Type 2A appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03146078 reports 14 study locations spanning 9 distinct geographic areas — top geographies include Other, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03146078 about?
NCT03146078 is a clinical study titled "Rate of Progression in USH2A-related Retinal Degeneration". The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39)...
What is the current status of trial NCT03146078?
This trial is currently active not recruiting. The enrollment target is 127 participants. The study started on 2017-08-11. Estimated completion is 2029-12.
What conditions does trial NCT03146078 study?
This clinical trial studies the following conditions: Usher Syndrome, Type 2A, Retinitis Pigmentosa 39. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03146078?
This trial is sponsored by Jaeb Center for Health Research, which has 134 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03146078 being conducted?
This trial has 14 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.